These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 16085935)

  • 1. Structural and mutational analyses of the molecular interactions between the catalytic domain of factor XIa and the Kunitz protease inhibitor domain of protease nexin 2.
    Navaneetham D; Jin L; Pandey P; Strickler JE; Babine RE; Abdel-Meguid SS; Walsh PN
    J Biol Chem; 2005 Oct; 280(43):36165-75. PubMed ID: 16085935
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of factor XIa (FXIa) catalytic domain exosite residues in substrate catalysis and inhibition by the Kunitz protease inhibitor domain of protease nexin 2.
    Su YC; Miller TN; Navaneetham D; Schoonmaker RT; Sinha D; Walsh PN
    J Biol Chem; 2011 Sep; 286(36):31904-14. PubMed ID: 21778227
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanisms and specificity of factor XIa and trypsin inhibition by protease nexin 2 and basic pancreatic trypsin inhibitor.
    Navaneetham D; Sinha D; Walsh PN
    J Biochem; 2010 Oct; 148(4):467-79. PubMed ID: 20647553
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The kunitz protease inhibitor domain of protease nexin-2 inhibits factor XIa and murine carotid artery and middle cerebral artery thrombosis.
    Wu W; Li H; Navaneetham D; Reichenbach ZW; Tuma RF; Walsh PN
    Blood; 2012 Jul; 120(3):671-7. PubMed ID: 22674803
    [TBL] [Abstract][Full Text] [Related]  

  • 5. P1 and P2' site mutations convert protease nexin-2 from a factor XIa inhibitor to a plasmin inhibitor.
    Navaneetham D; Wu W; Li H; Sinha D; Tuma RF; Walsh PN
    J Biochem; 2013 Feb; 153(2):221-31. PubMed ID: 23172304
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protease nexin II interactions with coagulation factor XIa are contained within the Kunitz protease inhibitor domain of protease nexin II and the factor XIa catalytic domain.
    Badellino KO; Walsh PN
    Biochemistry; 2000 Apr; 39(16):4769-77. PubMed ID: 10769134
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Crystal structures of the FXIa catalytic domain in complex with ecotin mutants reveal substrate-like interactions.
    Jin L; Pandey P; Babine RE; Gorga JC; Seidl KJ; Gelfand E; Weaver DT; Abdel-Meguid SS; Strickler JE
    J Biol Chem; 2005 Feb; 280(6):4704-12. PubMed ID: 15545266
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhanced plasmin inhibition by a reactive center lysine mutant of the Kunitz-type protease inhibitor domain of the amyloid beta-protein precursor.
    Van Nostrand WE; Schmaier AH; Siegel RS; Wagner SL; Raschke WC
    J Biol Chem; 1995 Sep; 270(39):22827-30. PubMed ID: 7559414
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tissue expression, protease specificity, and Kunitz domain functions of hepatocyte growth factor activator inhibitor-1B (HAI-1B), a new splice variant of HAI-1.
    Kirchhofer D; Peek M; Li W; Stamos J; Eigenbrot C; Kadkhodayan S; Elliott JM; Corpuz RT; Lazarus RA; Moran P
    J Biol Chem; 2003 Sep; 278(38):36341-9. PubMed ID: 12815039
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structural role of Gly(193) in serine proteases: investigations of a G555E (GLY193 in chymotrypsin) mutant of blood coagulation factor XI.
    Schmidt AE; Ogawa T; Gailani D; Bajaj SP
    J Biol Chem; 2004 Jul; 279(28):29485-92. PubMed ID: 15090552
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutation of surface residues to promote crystallization of activated factor XI as a complex with benzamidine: an essential step for the iterative structure-based design of factor XI inhibitors.
    Jin L; Pandey P; Babine RE; Weaver DT; Abdel-Meguid SS; Strickler JE
    Acta Crystallogr D Biol Crystallogr; 2005 Oct; 61(Pt 10):1418-25. PubMed ID: 16204896
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of the factor XI variant Arg184Gly suggests a structural basis for factor IX binding to factor XIa.
    Geng Y; Verhamme IM; Sun MF; Bajaj SP; Emsley J; Gailani D
    J Thromb Haemost; 2013 Jul; 11(7):1374-84. PubMed ID: 23617568
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of a heparin-binding site on the catalytic domain of factor XIa: mechanism of heparin acceleration of factor XIa inhibition by the serpins antithrombin and C1-inhibitor.
    Yang L; Sun MF; Gailani D; Rezaie AR
    Biochemistry; 2009 Feb; 48(7):1517-24. PubMed ID: 19178150
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Contributions of basic amino acids in the autolysis loop of factor XIa to serpin specificity.
    Rezaie AR; Sun MF; Gailani D
    Biochemistry; 2006 Aug; 45(31):9427-33. PubMed ID: 16878977
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Unusual proteolytic activation of pro-hepatocyte growth factor by plasma kallikrein and coagulation factor XIa.
    Peek M; Moran P; Mendoza N; Wickramasinghe D; Kirchhofer D
    J Biol Chem; 2002 Dec; 277(49):47804-9. PubMed ID: 12372819
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fasxiator, a novel factor XIa inhibitor from snake venom, and its site-specific mutagenesis to improve potency and selectivity.
    Chen W; Carvalho LP; Chan MY; Kini RM; Kang TS
    J Thromb Haemost; 2015 Feb; 13(2):248-61. PubMed ID: 25418421
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, synthesis, and biological evaluation of peptidomimetic inhibitors of factor XIa as novel anticoagulants.
    Lin J; Deng H; Jin L; Pandey P; Quinn J; Cantin S; Rynkiewicz MJ; Gorga JC; Bibbins F; Celatka CA; Nagafuji P; Bannister TD; Meyers HV; Babine RE; Hayward NJ; Weaver D; Benjamin H; Stassen F; Abdel-Meguid SS; Strickler JE
    J Med Chem; 2006 Dec; 49(26):7781-91. PubMed ID: 17181160
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Zinc (II) selectively enhances the inhibition of coagulation factor XIa by protease nexin-2/amyloid beta-protein precursor.
    Van Nostrand WE
    Thromb Res; 1995 Apr; 78(1):43-53. PubMed ID: 7778065
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Functional role of residue 193 (chymotrypsin numbering) in serine proteases: influence of side chain length and beta-branching on the catalytic activity of blood coagulation factor XIa.
    Schmidt AE; Sun MF; Ogawa T; Bajaj SP; Gailani D
    Biochemistry; 2008 Feb; 47(5):1326-35. PubMed ID: 18186617
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibitory properties of separate recombinant Kunitz-type-protease-inhibitor domains from tissue-factor-pathway inhibitor.
    Petersen LC; Bjørn SE; Olsen OH; Nordfang O; Norris F; Norris K
    Eur J Biochem; 1996 Jan; 235(1-2):310-6. PubMed ID: 8631347
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.